Impact of source of infection and vancomycin AUC0–24/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus.

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality P. Wittenhagen,

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Gram-positive infections: lessons learnt and novel solutions

New epidemiology of Staphylococcus aureus infection in Asia

G. Cornaglia, A. Lönnroth, M. Struelens

Molecular characterization of methicillin-resistant Staphylococcus aureus isolated over a 2-year period in a Qatari hospital from multinational patients

Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis T. Steinmetz, N.

European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years.

The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram- positive bacteria M.J. Rybak Clinical Microbiology and Infection

European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after.

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

J.-P. Van geertruyden Clinical Microbiology and Infection

In vitro activity of cefpirome and vancomycin in combination against gentamicin- susceptible and gentamicin-resistant Staphylococcus aureus A. Carricajo,

Clinical impact of antibiotic-resistant Gram-positive pathogens

Cost-effectiveness of universal MRSA screening on admission to surgery

Clonal complex 398 methicillin-susceptible Staphylococcus aureus bloodstream infections are associated with high mortality K. Bouiller, H. Gbaguidi-Haore,

European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after.

Antimicrobial drug use and infection control practices associated with the prevalence of methicillin-resistant Staphylococcus aureus in European hospitals

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

J.-P. Stahl Clinical Microbiology and Infection

Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia? M. Paul, N. Zemer-Wassercug, O.

Is the prevalence of antibiotic-resistant organisms changing in Canadian hospitals? Comparison of point-prevalence survey results in 2010 and 2012 V.

Use of surveillance cultures and enteral vancomycin to control methicillin-resistant Staphylococcus aureus in a paediatric intensive care unit K. Thorburn,

Appropriate vs. inappropriate antimicrobial therapy

Bacteriophages as a reservoir of extended-spectrum β -lactamase and fluoroquinolone resistance genes in the environment E. Marti, E. Variatza, J.L. Balcázar

W. Witte, B. Pasemann, C. Cuny Clinical Microbiology and Infection

Vector control: a cornerstone in the malaria elimination campaign

Y. Maor, N. Belausov, D. Ben-David, G. Smollan, N. Keller, G. Rahav

The use and therapeutic drug monitoring of teicoplanin in the UK

Low prevalence of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in Belgian hospitals C. Nonhoff, O. Denis,

A variant of the Southern German clone of methicillin-resistant Staphylococcus aureus is predominant in Croatia A. Budimir, R.H. Deurenberg, Z. Bošnjak,

Bacterial resistance—the clinical challenge

Risk factors and mortality of healthcare-associated and community-acquired Staphylococcus aureus bacteraemia M. Bassetti, E.M. Trecarichi, A. Mesini,

Evaluation of three chromogenic media (MRSA-ID, MRSA-Select and CHROMagar MRSA) and ORSAB for surveillance cultures of methicillin-resistant Staphylococcus.

Evaluation of vancomycin MIC creep in methicillin-resistant Staphylococcus aureus infections—a systematic review and meta-analysis R. Diaz, V. Afreixo,

Body site colonization in patients with community-associated methicillin-resistant Staphylococcus aureus and other types of S. aureus skin infections

Transmissibility of livestock-associated methicillin-resistant Staphylococcus aureus (ST398) in Dutch hospitals M.W.M. Wassenberg, M.C.J. Bootsma, A.

M. Aires-de-Sousa Clinical Microbiology and Infection

Voriconazole concentrations and outcome of invasive fungal infections

Y. Tveten, A. Jenkins, A.G. Allum, B.-E. Kristiansen

A.W. Karchmer Clinical Microbiology and Infection

Effect of metronidazole versus standard care on length of stay of patients admitted with severe infectious mononucleosis: a randomized controlled trial

P.M. Hawkey Clinical Microbiology and Infection

Strain relatedness of meticillin-resistant Staphylococcus aureus isolates recovered from patients with repeated bacteraemia C-H. Liao, C-C. Lai, S-Y.

Current experience in treating invasive zygomycosis with posaconazole

Community-associated Staphylococcus aureus infections and nasal carriage among children: molecular microbial data and clinical characteristics G. Sdougkos,

Clinical infection services—the Leiden experience

Sequential time to positivity of blood cultures can be a predictor of prognosis of patients with persistent Staphylococcus aureus bacteraemia M.-S. Hsu,

Correlation between time to positivity of blood cultures with clinical presentation and outcomes in patients with Klebsiella pneumoniae bacteraemia: prospective.

G.M. Rossolini, E. Mantengoli Clinical Microbiology and Infection

Clinical Microbiology and Infection

J.-M. Rolain, C. Abat, P. Brouqui, D. Raoult

Predictors of clinical and microbiological treatment failure in patients with methicillin- resistant Staphylococcus aureus (MRSA) bacteraemia: a retrospective.

Rise and subsequent decline of community-associated methicillin resistant Staphylococcus aureus ST30-IVc in Copenhagen, Denmark through an effective search.

S. Tom, J. C. Galbraith, L. Valiquette, G. Jacobsson, P. Collignon, H

E. Tacconelli Clinical Microbiology and Infection

Panton–Valentine leukocidin-encoding bacteriophage and gene sequence variation in community-associated methicillin-resistant Staphylococcus aureus J.A.

Cost-effectiveness of adding decolonization to a surveillance strategy of screening and isolation for methicillin-resistant Staphylococcus aureus carriers

J. Wilson, S. Elgohari, D. M. Livermore, B. Cookson, A. Johnson, T

A. Manzur, F. Gudiol Clinical Microbiology and Infection

Risk-factors and predictors of mortality in patients colonised with vancomycin-resistant enterococci V. Sakka, S. Tsiodras, L. Galani, A. Antoniadou,

W. Witte Clinical Microbiology and Infection

B.A. Cunha Clinical Microbiology and Infection

J.L. Balcázar Clinical Microbiology and Infection

G.C. Schito Clinical Microbiology and Infection

D.A. Robinson, M.C. Enright Clinical Microbiology and Infection

Impact of antibiotic restrictions: the patient's perspective

J. Segreti Clinical Microbiology and Infection

The future of diagnostic bacteriology

Presentation transcript:

Impact of source of infection and vancomycin AUC0–24/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia N. Ghosh, R. Chavada, M. Maley, S.J. van Hal Clinical Microbiology and Infection Volume 20, Issue 12, Pages O1098-O1105 (December 2014) DOI: 10.1111/1469-0691.12695 Copyright © 2014 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 1 Scatterplot of measured vancomycin trough levels at steady state and vancomycin AUC0–24/MICBMD. Lines represent recommended vancomycin trough targets on the x-axis and vancomycin AUC0–24/MICBMD on the y-axis. Clinical Microbiology and Infection 2014 20, O1098-O1105DOI: (10.1111/1469-0691.12695) Copyright © 2014 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 2 Box plots for vancomycin AUC0–24/MICBMD values in patients experiencing treatment failure or success stratified by source of MRSA bacteraemia. Source of bacteraemia grouped into one of three groups based on overall mortality risk (see text for details). Median and interquartile AUC0–24/MICBMD values are represented by boxplots with whiskers representing minimum and maximum values. Circles represent outliers. Clinical Microbiology and Infection 2014 20, O1098-O1105DOI: (10.1111/1469-0691.12695) Copyright © 2014 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 3 The proportion of patients not responding to vancomycin by source of bacteraemia when AUC24/MICBMD values were above and below CART-identified source-specific targets. Source of bacteraemia grouped into one of three groups based on overall mortality risk (see text for details). Clinical Microbiology and Infection 2014 20, O1098-O1105DOI: (10.1111/1469-0691.12695) Copyright © 2014 European Society of Clinical Infectious Diseases Terms and Conditions